Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)
Public ClinicalTrials.gov record NCT00076375. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Two Concentrations of Nanocrystalline Silver Cream (NPI) Applied Twice Daily in Adults With Mild to Moderate Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Nanocrystalline silver (very small particles of silver) is the active ingredient in Acticoat dressings, which have been approved for the treatment of burns and other wounds. Silver has been used for decades as an effective antimicrobial agent. In animal studies, nanocrystalline silver cream (NPI) has also demonstrated anti-inflammatory activity. Thus, nanocrystalline silver cream is being evaluated in the treatment of inflammatory skin conditions such as atopic dermatitis (eczema). Approximately 180 study subjects with a definitive diagnosis of mild to moderate eczema will be enrolled in this study. Subjects will be randomly assigned to treatment with placebo, 0.5% NPI or 1% NPI for the 6-week treatment period. Assessments of treatment effect and safety will be performed weekly. Upon completion of the study, subjects may be eligible for 12 weeks of open-label treatment with 1% NPI.
Study identification
- NCT ID
- NCT00076375
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2003
- Primary completion
- Not listed
- Completion
- Mar 31, 2004
- Last update posted
- Jun 23, 2005
2003 – 2004
United States locations
- U.S. sites
- 19
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Radiant Research | Birmingham | Alabama | 35209 | — |
| Medical Affliated Research Centers, Inc. | Huntsville | Alabama | 35801 | — |
| National Jewish Medical & Research Center | Denver | Colorado | 80206 | — |
| nTouch Research | Washington D.C. | District of Columbia | 20037 | — |
| Radiant Research | West Palm Beach | Florida | 33407 | — |
| Radiant Research | Boise | Idaho | 83704 | — |
| Radiant Research | Overland Park | Kansas | 66215 | — |
| Radiant Research | St Louis | Missouri | 63141 | — |
| Sadick Dermatology & Aesthetic Surgery | New York | New York | 10021 | — |
| Mount Sinai School of Medicine | New York | New York | 10029 | — |
| Clinical Research of Winston-Salem, Inc. | Winston-Salem | North Carolina | 27103 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Radiant Research | Columbus | Ohio | 43212 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Radiant Research | Philadelphia | Pennsylvania | 19115 | — |
| National Allergy, Asthma & Urticaria Centers of Charleston, P.A. | Charleston | South Carolina | 29407 | — |
| Radiant Research | Greer | South Carolina | 29605 | — |
| ACE Research Specialists, Inc. | Nashville | Tennessee | 37203 | — |
| Radiant Research | Lakewood | Washington | 98499 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00076375, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2005 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00076375 live on ClinicalTrials.gov.